ZyVersa Therapeutics Announces Publication in the Journal Circulation That Demonstrates the Role of Inflammasome Activation in Hypertrophic Heart Disease Induced by Mechanical Stress

2 years ago

Mechanical stress on the heart, such as high blood pressure, initiates NLRP3-induced inflammation through heart-brain interactions, causing heart enlargement (hypertrophic…

MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma

2 years ago

MW005 shown to be safe and well-tolerated Data provide clinical efficacy proof-of-concept based on clearance of target lesions YAVNE, Israel,…

TerrAscend Reaches Four Dispensary Cap in Maryland with Closing of Herbiculture Acquisition

2 years ago

Acquisition expected to be immediately accretive on an EBITDA and cashflow basisTORONTO, July 10, 2023 (GLOBE NEWSWIRE) -- TerrAscend Corp. (“TerrAscend”…

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2023 Financial Results on August 9, 2023

2 years ago

CANTON, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on…

Syneos Health Appoints Hillary Bochniak as Chief Human Resources Officer

2 years ago

Human Resources Leader with Nearly 30 Years of Experience and Commitment to Professional Services EnvironmentMORRISVILLE, N.C., July 10, 2023 (GLOBE NEWSWIRE)…

Evelo Biosciences Announces $25.5 Million Private Placement

2 years ago

CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel…

Societal CDMO Selected by Spinnaker Biosciences to Provide CDMO Services to Support Clinical Development of Novel Therapeutic Candidate

2 years ago

Activities will be Conducted at Societal CDMO’s San Diego Facility and Span Analytic Method Transfer, Process Development, and CGMP ManufacturingSAN…

Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer

2 years ago

Positive FDA Feedback Supports IOV-LUN-202 Trial Design for Accelerated Approval of TIL Therapy in Post-Anti-PD-1 Advanced Non-Small Cell Lung Cancer (NSCLC)…

European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients

2 years ago

HOUSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation…